Actavis rejected $15 billion offer from Mylan: source

By Soyoung Kim and Jessica Toonkel NEW YORK (Reuters) – Actavis Inc received and rejected a takeover offer from Mylan Inc last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation told Reuters on Tuesday. Mylan’s cash and stock bid for its larger rival, which came in early last week, valued Actavis at $120 per share, the person said, asking not to be identified because the matter is not public. …